Research Reveals Online Weight Loss Drug Risks

A recent investigation revealed alarming practices among websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly. Over half of the 79 reviewed sites failed to disclose that their products lacked FDA approval, with many misleadingly implying approval and not informing patients of risks. Outgoing FDA Commissioner Robert Califf expressed grave concerns about the online compounding industry, highlighting the difficulty consumers face in assessing the quality of these drugs. He noted that high prices of branded drugs exacerbate the issue, pushing consumers towards these unregulated alternatives. The lack of oversight in compounded medications raises serious safety and efficacy concerns, especially given the rising demand for affordable weight loss solutions. Experts emphasize the need for stronger regulatory measures to protect consumers from potential dangers associated with these products.